Efficacy and Safety Assessment of T2347 Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to assess the efficacy and safety of T2347 (Latanoprost 0.005%
+ Timolol 0.5% unpreserved eye drops) versus Xalacom® in ocular hypertensive or glaucomatous
patients initially treated, stabilised by Xalacom® or generics (fixed combination Latanoprost
0.005% + Timolol 0.5% preserved eye drops).